05.01.2023 - WALTHAM, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) - Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Praveen .
Morphic Congratulates Timothy A. Springer, PhD as 2022 Albert Lasker Basic Medical Research Award Honoree streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Morphic Announces Corporate Highlights and Financial Results for the Second Quarter 2022 Continued enrollment of EMERALD-1 phase 2a trial of MORF-057 in. | August 3, 2022
WALTHAM, Mass., May 18, 2022 (GLOBE NEWSWIRE) Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases,